Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status:
Active, not recruiting
Trial end date:
2023-01-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether copanlisib in combination with rituximab is
superior to placebo in combination with rituximab in prolonging progression free survival
(PFS) in patients with relapsed iNHL who have received one or more lines of treatment,
including rituximab and who either had a treatment-free interval of ≥ 12 months after
completion of the last rituximab-containing treatment, or who are unwilling to receive
chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or
residual toxicity.